Improvements in clinical outcomes with afatinib vs chemotherapy in both LL3 and LL6, particularly in patients with tumours harbouring common EGFR mutations (Del19/L858R), have been previously reported (Sequist et al, 2013; Wu et al, 2014; Yang et al, 2015). The gene discussed is EGFR; the disease is neoplasm.